Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169420 | 0.82 | IDO1 (0.50) | IDO1 | |
| SCHEMBL8226137 | 0.82 | AKR1B1 (0.41) | AKR1B1CTSSFFAR4IDO1P2RX7 | |
| SCHEMBL23536723 | 0.81 | CTSS (0.43) | CTSSIDO1P2RX7 | |
| SCHEMBL6862729 | 0.81 | IDO1 (0.38) | CTSSIDO1PTGS2 | |
| SCHEMBL2360363 | 0.80 | GABRA1 (0.41) | CTSSIDO1PTGS2 | |
| SCHEMBL13437613 | 0.80 | P2RX7 (0.42) | CTSSFFAR4P2RX7 | |
| SCHEMBL1607335 | 0.79 | AKR1B1 (0.46) | AKR1B1CTSSFFAR4IDO1P2RX7 | |
| SCHEMBL5415312 | 0.79 | GABRA1 (0.46) | AKR1B1CTSSIDO1P2RX7EPHX2 | |
| SCHEMBL41932 | 0.79 | IDO1 (0.44) | AKR1B1FFAR4IDO1P2RX7 | |
| SCHEMBL27190814 | 0.78 | AKR1B1 (0.32) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759098-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | Genentech, Inc. (US) | 2021-01-06 | — | — | EP | disclosed |
| WO-2019165290-A1 | PYRIDINE-SULFONAMIDE COMPOUNDS AND THEIR USE AGAINST PAIN AND RELATED CONDITIONS | GENENTECH, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2017-08-31 | — | — | US | disclosed |
| CN-104011046-B | Aminopyrimidine kinase inhibitors | 嘉世高制药公司 | 2017-05-03 | — | — | CN | disclosed |
| US-9629840-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2017-04-25 | — | — | US | disclosed |
| EP-2776432-B1 | AMINOPYRIMIDINE KINASE INHIBITORS | JASCO PHARMACEUTICALS LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | P2K DYNAMICS INC. | 2015-07-23 | — | — | US | disclosed |
| US-8927525-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2776432-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | P2K DYNAMICS INC. | 2013-11-21 | — | — | US | disclosed |
| WO-2013066684-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | Jasco Pharmaceuticals, LLC (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-2408754-A1 | Triazole derivatives as vasopressin-receptor inhibitors for treating cardiac insufficiency | Bayer Pharma Aktiengesellschaft (DE) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010105750-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247367-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | AKR1B1 3246/4885CTSS 4472/4885FFAR4 4755/4885 |
| US-20130310342-A1 | Aminopyrimidine Kinase Inhibitors | PIM1, PIM2, PIM3 | AKR1B1 3134/4885CTSS 4487/4885FFAR4 4752/4885 |
| US-20150202205-A1 | AMINOPYRIMIDINE KINASE INHIBITORS | PIM1, PIM2, PIM3 | AKR1B1 3134/4885CTSS 4487/4885FFAR4 4752/4885 |
| US-10336743-B2 | Aminopyrimidine kinase inhibitors | PIM1, PIM2, PIM3 | AKR1B1 3134/4885CTSS 4487/4885FFAR4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.